Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 24, 2017

View Archived Issues

NIH launches MarkVCID consortium to develop small vessel disease biomarkers

Cyclacel Pharmaceuticals reports results from pivotal phase III SEAMLESS trial in patients with AML

CYP3A5 and ABCB1 genes as predictors of sunitinib toxicity in patients with renal cell carcinoma

FDA clears expanded use of Vidas Brahms PCT Assay

FDA allows marketing of PhenoTest BC Kit

Phase I results for Diamyd vaccine presented for type 1 diabetes

Rexahn Pharmaceuticals begins enrolling patients in phase IIa study of Supinoxin in TNBC

Janssen Pharmaceutica divulges novel FFA1 receptor agonists

ViiV Healthcare UK identifies novel HIV integrase inhibitors

UAB developing peptide with potential for homozygous familial hypercholesterolemia

Tocagen gives update on phase II Toca 5 study of Toca-511/Toca-FC

Novel IRAK-4 inhibitors discovered at Beijing Hanmi Pharmaceutical

Actelion describes new antibacterials

Roche discloses excitatory amino acid transporter 3 inhibitors

Children's National Health System presents initial data from RESOLVE study of TAA-L therapy

Bavarian Nordic reports 6-month follow-up data from phase I study of RSV vaccine candidate

Incyte announces multiyear research collaboration with Abramson Cancer Center

Sofosbuvir/velpatasvir granted orphan status in the U.S. for pediatric hepatitis C virus infection

Medivir describes activity of nucleotide prodrug MIV-818

Caladrius Biosciences receives grant for development of cell therapy CLBS-03

Reata initiates phase II/III study of bardoxolone methyl to treat Alport syndrome-associated CKD

DLL3 proven as a poor prognostic biomarker in small-cell bladder cancer

Aphios to spin off Aphios Pharma to develop cannabis-based drugs for CNS disorders

Abivax reports discovery of molecules for treatment of dengue virus

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...